Department of Addiction Sciences, Taipei City Psychiatric Center, Taipei City Hospital, Taipei, Taiwan.
Center for Neuropsychiatric Research, National Health Research Institutes, Miaoli, Taiwan.
Subst Abuse Treat Prev Policy. 2024 Jul 8;19(1):34. doi: 10.1186/s13011-024-00616-8.
Evaluating the risk of relapse is a pivotal step in the treatment of patients with methamphetamine use disorder (MUD). The 30-item Stimulant Relapse Risk Scale (SRRS) was originally developed in Japan to meet the demand. This study examined the reliability, validity, and factor structure of the Chinese version of the SRRS for patients with MUD.
247 patients with MUD self-rated the Chinese version of the SRRS. Cronbach's alpha coefficients and inter-item correlation analysis were used to assess the internal consistency reliability. Construct validity was determined through confirmatory factor analysis (CFA), and concurrent validity was examined using the visual analogue scale (VAS) for drug craving and the severity of dependence scale (SDS). We followed the participants for 1 year and assessed the predictive validity based on the correlation of the scores of the Chinese version of the SRRS with the relapse rate within 3, 6, and 12 months of follow-up.
CFA revealed satisfactory model fit estimates for the 22-item Chinese version of the SRRS that consisted of four subscales. The four-factored 22-item Chinese version of the SRRS had adequate internal consistency with Cronbach's alphas ranging from 0.76 to 0.92. The 22-item Chinese version of the SRRS scores were significantly correlated with the VAS and SDS scores as well as the relapse rate within 3, 6, and 12 months, indicating good concurrent and predictive validity of this scale. The receiver operating characteristic curve revealed a cutoff score of 40 could discriminate between participants with (SDS score ≥ 4) and without (SDS score < 4) methamphetamine dependence (area under the curve = 0.71, p < 0.01).
The 22-item Chinese version of the SRRS that consists of four subscales is a valid and reliable instrument to assess the relapse risk in patients with MUD.
评估复发风险是治疗甲基苯丙胺使用障碍(MUD)患者的关键步骤。最初在日本开发了 30 项兴奋剂复发风险量表(SRRS)以满足需求。本研究检验了中文版 SRRS 在 MUD 患者中的信度、效度和因子结构。
247 名 MUD 患者自评中文版 SRRS。采用克朗巴赫α系数和条目间相关分析评估内部一致性信度。通过验证性因子分析(CFA)确定结构效度,并使用药物渴求视觉模拟量表(VAS)和依赖严重程度量表(SDS)检验同时效度。我们对参与者进行了为期 1 年的随访,并根据中文版 SRRS 评分与 3、6 和 12 个月随访期间复发率的相关性评估预测效度。
CFA 显示,由四个分量表组成的 22 项中文版 SRRS 具有令人满意的模型拟合估计值。具有四个因子的 22 项中文版 SRRS 具有足够的内部一致性,克朗巴赫α系数范围为 0.76 至 0.92。中文版 SRRS 评分与 VAS 和 SDS 评分以及 3、6 和 12 个月内的复发率显著相关,表明该量表具有良好的同时和预测效度。受试者工作特征曲线显示,区分有(SDS 评分≥4)和无(SDS 评分<4)甲基苯丙胺依赖的分界值为 40(曲线下面积=0.71,p<0.01)。
由四个分量表组成的 22 项中文版 SRRS 是评估 MUD 患者复发风险的有效、可靠工具。